Department of Gastroenterology, Dokkyo Medical University, Mibu, Tochigi, Japan.
Aliment Pharmacol Ther. 2010 Apr;31(8):824-33. doi: 10.1111/j.1365-2036.2010.04250.x. Epub 2010 Feb 2.
Helicobacter pylori eradication therapy alone is not sufficient to heal all gastric ulcers.
To verify the efficacy of treatment with irsogladine maleate between the termination and assessment of treatment for eradicating H. pylori in a double-blind study.
Three hundred and twenty-two patients with a single H. pylori-positive gastric ulcer were given eradication treatment, then assigned randomly to a treatment group [given 4 mg/day irsogladine maleate (n = 150)] or a control group [given a placebo (n = 161)]. The gastric ulcer healing rates were compared after 7 weeks of treatment.
The healing rate was significantly higher in the irsogladine maleate group (83.0%) than in the placebo group (72.2%; chi2 test, P = 0.0276). In the subgroup analysis of cases of eradication failure, the gastric ulcer healing rate was significantly higher in the irsogladine maleate group (57.9%) than in the placebo group (26.1%; chi2 test, P = 0.0366).
Irsogladine maleate was effective for treating gastric ulcer after H. pylori eradication. The high healing rates observed in patients with or without successful eradication demonstrate the usefulness of irsogladine maleate treatment regardless of the outcome of eradication.
单独使用幽门螺杆菌根除疗法不足以治愈所有胃溃疡。
在一项双盲研究中验证在终止和评估幽门螺杆菌根除治疗时使用马来酸伊索拉定的治疗效果。
将 322 例单一幽门螺杆菌阳性胃溃疡患者给予根除治疗,然后随机分为治疗组[给予 4mg/天马来酸伊索拉定(n=150)]或对照组[给予安慰剂(n=161)]。治疗 7 周后比较胃溃愈合率。
马来酸伊索拉定组的愈合率(83.0%)明显高于安慰剂组(72.2%;卡方检验,P=0.0276)。在根除失败病例的亚组分析中,马来酸伊索拉定组的胃溃疡愈合率(57.9%)明显高于安慰剂组(26.1%;卡方检验,P=0.0366)。
马来酸伊索拉定对幽门螺杆菌根除后胃溃疡的治疗有效。无论根除结果如何,在根除成功或失败的患者中观察到的高愈合率均表明马来酸伊索拉定治疗有用。